Get the Stockscreener App
264.48
1.62%
4.21
Beone Medicines Ltd Adr stock is traded at $264.48, with a volume of 259.32K.
It is up +1.62% in the last 24 hours and down -16.06% over the past month.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
See More
Previous Close:
$260.27
Open:
$261.64
24h Volume:
259.32K
Relative Volume:
1.12
Market Cap:
$27.44B
Revenue:
$5.76B
Net Income/Loss:
$514.49M
P/E Ratio:
59.02
EPS:
4.4813
Net Cash Flow:
$1.10B
1W Performance:
-2.08%
1M Performance:
-16.06%
6M Performance:
-17.11%
1Y Performance:
-4.36%
1-Day Range:
$261.50
$267.56
1-Week Range:
$253.95
$272.24
52-Week Range:
$239.25
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Name
Beone Medicines Ltd Adr
Sector
Industry
Phone
41-616851900
Address
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
264.48 | 27.44B | 5.76B | 514.49M | 1.10B | 4.4813 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Wolfe Research | Outperform |
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Nov-24-25 | Initiated | Truist | Buy |
| Sep-18-25 | Initiated | Barclays | Overweight |
| Apr-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-03-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-03-24 | Resumed | Morgan Stanley | Overweight |
| Sep-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-06-24 | Resumed | JP Morgan | Overweight |
| Sep-12-23 | Initiated | Macquarie | Outperform |
| Aug-17-23 | Initiated | Jefferies | Buy |
| Jul-17-23 | Initiated | Citigroup | Buy |
| Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-12-23 | Initiated | Daiwa Securities | Buy |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-09-22 | Resumed | JP Morgan | Overweight |
| Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-07-22 | Initiated | Deutsche Bank | Buy |
| Oct-12-21 | Initiated | Bernstein | Outperform |
| Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
| Mar-08-21 | Initiated | China Renaissance | Buy |
| Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
| Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
View All
Beone Medicines Ltd Adr Stock (ONC) Latest News
Barings LLC Reduces Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Here's How Much You Would Have Made Owning BeOne Medicines Stock In The Last 10 Years - Sahm
A Look At BeOne Medicines (ONC) Valuation After Analyst Upgrades And Positive ASCO 2026 Clinical Updates - Sahm
Capital International Sarl Raises Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines Ltd.Sponsored ADR $ONC Position Raised by Capital International Investors - MarketBeat
Is BeOne Medicines (ONC) Quietly Recasting Its Hematology Roots Into a Multi-Franchise Oncology Platform? - Sahm
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3 - sharewise.com
ONC Technical Analysis | Trend, Signals & Chart Patterns | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
《AI》BEONE MEDICINES(06160.HK) Displays Technical Pattern of Range Breakout - AASTOCKS.com
《AI》BEONE MEDICINES(06160.HK) Displays Technical Pattern of Triangle Breakout - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 5.1M shares at $176.8, $901.68M turnover - AASTOCKS.com
BEONE MEDICINES (06160.HK) An Taisite Approved in Mainland China for Second-line Treatment of Small Cell Lung Cancer - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 254.9K shares at $175.1, $44.633M turnover - AASTOCKS.com
CICC: Focus on Positive Capital Flow Impact from Index Review on BEONE MEDICINES (06160.HK), J&T EXPRESS-W (01519.HK), KNOWLEDGE ATLAS (02513.HK) and MINIMAX-W (00100.HK) - AASTOCKS.com
Marriott Upgraded, Roku Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Bearish block trade of BEONE MEDICINES(06160) 231.3K shares at $185.8, $42.976M turnover - AASTOCKS.com
BeOne Medicines Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR - TradingView
BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative - Sahm
HSI To Add J&T EXPRESS-W (01519.HK), CHALCO (02600.HK), BEONE MEDICINES (06160.HK) after Quarterly Review - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 212K shares at $184.5, $39.114M turnover - AASTOCKS.com
ONC Stock Price, Quote & Chart | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
BeOne Medicines Ltd.: BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts - FinanzNachrichten.de
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts - Via TT
Bearish block trade of BEONE MEDICINES(06160) 323.6K shares at $183.1, $59.251M turnover - AASTOCKS.com
BeOne Medicines Wins FDA Nod For BEQALZI In Mantle Cell Lymphoma - Sahm
ONC News | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
Bearish block trade of BEONE MEDICINES(06160) 206.1K shares at $175.1, $36.088M turnover - AASTOCKS.com
BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer - Sahm
BeiGene Must Face AbbVie's Chemical Trade Secret Claims - Law360
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma - ChartMill
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire Inc.
Apple Upgraded, American Express Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BeOne Medicines (ONC) Is Up 7.4% After Guidance Hike And Priority Review Win In HER2 Cancer - Sahm
Citi Raises BeOne Medicines Ltd. (ONC.US) TP to USD453; 1Q26 Results Strong - AASTOCKS.com
Sigma Planning Corp Sells 3,208 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Earnings Beat: BeOne Medicines AG Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
UBS Group AG Grows Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BOCI: BEONE MEDICINES 1Q Results Beat; Rating Buy Reiterated - AASTOCKS.com
G Sachs Raises BeOne Medicines Ltd. (ONC.US) TP to USD414.46, Rating Buy - AASTOCKS.com
UBS Raises BeOne Medicines Ltd. (ONC.US) TP to USD465, 1Q Results Strong - AASTOCKS.com
M Stanley Raises BeOne Medicines Ltd. (ONC.US) TP to USD395; 1Q Results Beat Expectations - AASTOCKS.com
BeOne Medicines Q1 Earnings Call Highlights - Yahoo Finance
BeOne Medicines (ONC) registers 398.9M ordinary shares for resale by major holders - Stock Titan
BEONE MEDICINES (06160.HK) 1Q Net Profit USD227 million Surges 178x YoY; Raises FY2026 Revenue Guidance - AASTOCKS.com
Is It Too Late To Consider BeOne Medicines (ONC) After Its 23% One Year Gain? - Sahm
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy - Sahm
BeOne Medicines files 2025 annual report with Shanghai STAR Market - Investing.com
Oil Shock, AI Tailwinds, And Portfolio Shifts Across Emerging Markets - Seeking Alpha
Chan Henry Lee Sells 332 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Is BeOne (ONC) Stock entering maturity stage | ONC Q4 2025 Earnings: BeOne Medicines Ltd. ADS misses EPS, no revenue releasedADR - Newser
Beone Medicines Ltd Adr Stock (ONC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
1.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):